PLGA nanoparticle formulation of RK-33: An RNA helicase inhibitor against DDX3

Guus Martinus Bol, Raheela Khan, Marise Rosa Heerma Van Voss, Saritha Tantravedi, Dorian Korz, Yoshinori Kato, Venu Raman

Research output: Contribution to journalArticle

Abstract

Background: The DDX3 helicase inhibitor RK-33 is a newly developed anticancer agent that showed promising results in preclinical research (Bol et al. EMBO Mol Med, 7(5):648-649, 2015). However, due to the physicochemical and pharmacological characteristics of RK-33, we initiated development of alternative formulations of RK-33 by preparing sustained release nanoparticles that can be administered intravenously. Methods: In this study, RK-33 was encapsulated in poly(lactic-co-glycolic acid) (PLGA), one of the most well-developed biodegradable polymers, using the emulsion solvent evaporation method. Results: Hydrodynamic diameter of RK-33-PLGA nanoparticles was about 245 nm with a negative charge, and RK-33-PLGA nanoparticles had a payload of 1.4 % RK-33. RK-33 was released from the PLGA nanoparticles over 7 days (90 ± 5.7 % released by day 7) and exhibited cytotoxicity to human breast carcinoma MCF-7 cells in a time-dependent manner. Moreover, RK-33-PLGA nanoparticles were well tolerated, and systemic retention of RK-33 was markedly improved in normal mice. Conclusions: PLGA nanoparticles have a potential as a parenteral formulation of RK-33.

Original languageEnglish (US)
Pages (from-to)821-827
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume76
Issue number4
DOIs
StatePublished - Sep 2 2015

Fingerprint

RNA Helicases
Nanoparticles
Biodegradable polymers
MCF-7 Cells
Hydrodynamics
Cytotoxicity
Emulsions
Antineoplastic Agents
polylactic acid-polyglycolic acid copolymer
Polymers
Evaporation
Pharmacology
Breast Neoplasms
Research

Keywords

  • DDX3
  • Drug release
  • Nanoparticles
  • PLGA
  • RK-33

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology
  • Medicine(all)

Cite this

PLGA nanoparticle formulation of RK-33 : An RNA helicase inhibitor against DDX3. / Bol, Guus Martinus; Khan, Raheela; Heerma Van Voss, Marise Rosa; Tantravedi, Saritha; Korz, Dorian; Kato, Yoshinori; Raman, Venu.

In: Cancer Chemotherapy and Pharmacology, Vol. 76, No. 4, 02.09.2015, p. 821-827.

Research output: Contribution to journalArticle

Bol, GM, Khan, R, Heerma Van Voss, MR, Tantravedi, S, Korz, D, Kato, Y & Raman, V 2015, 'PLGA nanoparticle formulation of RK-33: An RNA helicase inhibitor against DDX3', Cancer Chemotherapy and Pharmacology, vol. 76, no. 4, pp. 821-827. https://doi.org/10.1007/s00280-015-2851-3
Bol, Guus Martinus ; Khan, Raheela ; Heerma Van Voss, Marise Rosa ; Tantravedi, Saritha ; Korz, Dorian ; Kato, Yoshinori ; Raman, Venu. / PLGA nanoparticle formulation of RK-33 : An RNA helicase inhibitor against DDX3. In: Cancer Chemotherapy and Pharmacology. 2015 ; Vol. 76, No. 4. pp. 821-827.
@article{522cd968e1984defa00a018dd2575906,
title = "PLGA nanoparticle formulation of RK-33: An RNA helicase inhibitor against DDX3",
abstract = "Background: The DDX3 helicase inhibitor RK-33 is a newly developed anticancer agent that showed promising results in preclinical research (Bol et al. EMBO Mol Med, 7(5):648-649, 2015). However, due to the physicochemical and pharmacological characteristics of RK-33, we initiated development of alternative formulations of RK-33 by preparing sustained release nanoparticles that can be administered intravenously. Methods: In this study, RK-33 was encapsulated in poly(lactic-co-glycolic acid) (PLGA), one of the most well-developed biodegradable polymers, using the emulsion solvent evaporation method. Results: Hydrodynamic diameter of RK-33-PLGA nanoparticles was about 245 nm with a negative charge, and RK-33-PLGA nanoparticles had a payload of 1.4 {\%} RK-33. RK-33 was released from the PLGA nanoparticles over 7 days (90 ± 5.7 {\%} released by day 7) and exhibited cytotoxicity to human breast carcinoma MCF-7 cells in a time-dependent manner. Moreover, RK-33-PLGA nanoparticles were well tolerated, and systemic retention of RK-33 was markedly improved in normal mice. Conclusions: PLGA nanoparticles have a potential as a parenteral formulation of RK-33.",
keywords = "DDX3, Drug release, Nanoparticles, PLGA, RK-33",
author = "Bol, {Guus Martinus} and Raheela Khan and {Heerma Van Voss}, {Marise Rosa} and Saritha Tantravedi and Dorian Korz and Yoshinori Kato and Venu Raman",
year = "2015",
month = "9",
day = "2",
doi = "10.1007/s00280-015-2851-3",
language = "English (US)",
volume = "76",
pages = "821--827",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - PLGA nanoparticle formulation of RK-33

T2 - An RNA helicase inhibitor against DDX3

AU - Bol, Guus Martinus

AU - Khan, Raheela

AU - Heerma Van Voss, Marise Rosa

AU - Tantravedi, Saritha

AU - Korz, Dorian

AU - Kato, Yoshinori

AU - Raman, Venu

PY - 2015/9/2

Y1 - 2015/9/2

N2 - Background: The DDX3 helicase inhibitor RK-33 is a newly developed anticancer agent that showed promising results in preclinical research (Bol et al. EMBO Mol Med, 7(5):648-649, 2015). However, due to the physicochemical and pharmacological characteristics of RK-33, we initiated development of alternative formulations of RK-33 by preparing sustained release nanoparticles that can be administered intravenously. Methods: In this study, RK-33 was encapsulated in poly(lactic-co-glycolic acid) (PLGA), one of the most well-developed biodegradable polymers, using the emulsion solvent evaporation method. Results: Hydrodynamic diameter of RK-33-PLGA nanoparticles was about 245 nm with a negative charge, and RK-33-PLGA nanoparticles had a payload of 1.4 % RK-33. RK-33 was released from the PLGA nanoparticles over 7 days (90 ± 5.7 % released by day 7) and exhibited cytotoxicity to human breast carcinoma MCF-7 cells in a time-dependent manner. Moreover, RK-33-PLGA nanoparticles were well tolerated, and systemic retention of RK-33 was markedly improved in normal mice. Conclusions: PLGA nanoparticles have a potential as a parenteral formulation of RK-33.

AB - Background: The DDX3 helicase inhibitor RK-33 is a newly developed anticancer agent that showed promising results in preclinical research (Bol et al. EMBO Mol Med, 7(5):648-649, 2015). However, due to the physicochemical and pharmacological characteristics of RK-33, we initiated development of alternative formulations of RK-33 by preparing sustained release nanoparticles that can be administered intravenously. Methods: In this study, RK-33 was encapsulated in poly(lactic-co-glycolic acid) (PLGA), one of the most well-developed biodegradable polymers, using the emulsion solvent evaporation method. Results: Hydrodynamic diameter of RK-33-PLGA nanoparticles was about 245 nm with a negative charge, and RK-33-PLGA nanoparticles had a payload of 1.4 % RK-33. RK-33 was released from the PLGA nanoparticles over 7 days (90 ± 5.7 % released by day 7) and exhibited cytotoxicity to human breast carcinoma MCF-7 cells in a time-dependent manner. Moreover, RK-33-PLGA nanoparticles were well tolerated, and systemic retention of RK-33 was markedly improved in normal mice. Conclusions: PLGA nanoparticles have a potential as a parenteral formulation of RK-33.

KW - DDX3

KW - Drug release

KW - Nanoparticles

KW - PLGA

KW - RK-33

UR - http://www.scopus.com/inward/record.url?scp=84942195250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942195250&partnerID=8YFLogxK

U2 - 10.1007/s00280-015-2851-3

DO - 10.1007/s00280-015-2851-3

M3 - Article

C2 - 26330329

AN - SCOPUS:84942195250

VL - 76

SP - 821

EP - 827

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -